This bill enacts R.S. 22:1049.1, which mandates health coverage plans in Louisiana to provide coverage for genetic testing and medically necessary treatment for SCN2A-associated medical conditions, effective January 1, 2027. The bill defines key terms such as "genetic testing," "health coverage plan," "medically necessary treatment," and "SCN2A," which is a gene linked to various neurodevelopmental disorders. Coverage must include a range of treatments, including anti-seizure medications, rehabilitative services, and necessary medical equipment, as determined by the treating physician or advanced practice provider.

Additionally, the bill outlines the process for determining medical necessity, requiring written explanations for any denials of coverage, which can be appealed. Health coverage plans may impose prior authorization and cost-sharing requirements, but these must be applied fairly and cannot exceed those for other medical benefits. Importantly, coverage cannot be denied based on disability, developmental status, or preexisting conditions, and the benefits provided under this section are classified as rehabilitative or habilitative services for essential health benefits requirements. The provisions do not apply to limited benefit health insurance policies.